Willow Biosciences Inc.
Proprietary biomanufacturing platform using fermentation and synthetic biology to produce industrial ingredients and chemicals
- Sector
- Biotech
- Headquarters
- CALGARY, A0
- Founded
- 2019
- Latest Form D
- $1.2M, Nov 2020
- Total capital
- $1.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $1.2M
- 1 Form D · last Nov 2020
- 71 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 17 pending · first 2020
- Rank in peer group#43 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$1.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#43 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Al ForemanDirectorNamed in SEC Form D filings
- Chris SavileExecutive OfficerNamed in SEC Form D filings
- Christopher SpeedExecutive OfficerNamed in SEC Form D filings
- Donald H. ArchibaldDirectorNamed in SEC Form D filings
- Fotis H. KalantzisDirectorNamed in SEC Form D filings
- Jerry EricssonExecutive OfficerNamed in SEC Form D filings
Show all 12 people
- Mathias SchuetzExecutive OfficerNamed in SEC Form D filings
- Peter Seufer-WasserthalDirectorNamed in SEC Form D filings
- Sadiq H. LalaniDirectorNamed in SEC Form D filings
- Talkkari TroyExecutive OfficerNamed in SEC Form D filings
- Travis DoupeExecutive OfficerNamed in SEC Form D filings
- Trevor PetersExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 21- PendingCompositions And Methods For Enhancing Recombinant Biosynthesis Of CannabinoidsUSPTOApplication 18049603
- PendingCompositions and Methods for Recombinant Biosynthesis of CannabinoidsUSPTOApplication 17935491
- GrantedCompositions And Methods For Making Terpenoid Indole AlkaloidsUSPTOUS 11,072,613
Show all 21 patent records
- Compositions And Methods For Enhancing Recombinant Biosynthesis Of CannabinoidsSep 7, 2023 · Application 18049603Pending
- Compositions and Methods for Recombinant Biosynthesis of CannabinoidsJun 22, 2023 · Application 17935491Pending
- Compositions And Methods For Making Terpenoid Indole AlkaloidsJul 27, 2021 · US 11,072,613Granted
- N-alkylation Of Alkaloid CompoundsMar 25, 2021 · Application 16635224Pending
- Compositions And Methods For Making Noscapine And Synthesis Intermediates ThereofOct 6, 2020 · US 10,793,885Granted
- Methods and Compositions For Making Ephedrine and Related Alkaloid CompoundsJun 9, 2020 · US 10,676,767Granted
- Compositions and Methods For Making (S)-Norcoclaurine and (S)-Norlaudanosoline, and Synthesis Intermediates ThereofMay 26, 2020 · US 10,662,453Granted
- Compositions and Methods For Making Alkaloid MorphinansMay 23, 2019 · Application 16247972Pending
- Recombinant Polypeptides With Prenyltransferase Activity For Biosynthesis Of Cannabinoids And Hop CompoundsApplication 63384591Pending
- Recombinant Hosts And Genes For Biosynthesis Of Rare Cannabinoids And Rare Cannabinoid PrecursorsApplication 63124526Pending
- Production Of Glycosylated CannabinoidsApplication 63111005Pending
- Compositions And Methods For Enhancing Recombinant Biosynthesis Of CannabinoidsApplication 63017594Pending
- Compositions And Methods For Recombinant Biosynthesis Of CannabinoidsApplication 63001202Pending
- Recombinant Polypeptides For Enhanced Biosynthesis Of CannabinoidsApplication 63164510Pending
- Recombinant Olivetolic Acid Cyclase Polypeptides Engineered For Enhanced Biosynthesis Of CannabinoidsApplication PCTUS2022075170Pending
- Recombinant Olivetolic Acid Cyclase Polypeptides Engineered For Enhanced Biosynthesis Of CannabinoidsApplication 63341996Pending
- Recombinant Polypeptides For Enhanced Biosynthesis Of CannabinoidsApplication PCTUS2022021113Pending
- Recombinant Olivetolic Acid Cyclase Polypeptides Engineered For Enhanced Biosynthesis Of CannabinoidsApplication 63320421Pending
- Recombinant Thca Synthase Polypeptides Engineered For Enhanced Biosynthesis Of CannabinoidsApplication 63257523Pending
- Recombinant Olivetolic Acid Cyclase Polypeptides Engineered For Enhanced Biosynthesis Of CannabinoidsApplication 63235087Pending
- Recombinant Prenyltransferase Polypeptides Engineered For Enhanced Biosynthesis Of CannabinoidsApplication 63227747Pending
Related companies, and why
- Deepcell, Inc.Similar federal contract value in Biotech · null in contracts
- Neurelis, Inc.Similar federal contract value in Biotech · null in contracts
- Coeptis Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Validus Cellular Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Variant BioSimilar federal contract value in Biotech · null in contracts
- Therabene Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .